Cargando…

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes

BACKGROUND: No studies evaluated the role of F8 mutations in outcomes for low‐dose immune tolerance induction (ITI) in people with severe hemophilia A (SHA) with high‐titer inhibitors. OBJECTIVES: To explore the association between F8 mutation types and low‐dose ITI outcomes in children with SHA wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jie, Li, Zekun, Li, Gang, Huang, Kun, Ai, Di, Liu, Guoqing, Yao, Wanru, Xie, Xingjuan, Gu, Hao, Zhen, Yingzi, Chen, Zhenping, Wu, Runhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606347/
https://www.ncbi.nlm.nih.gov/pubmed/36313984
http://dx.doi.org/10.1002/rth2.12824
_version_ 1784818277579489280
author Sun, Jie
Li, Zekun
Li, Gang
Huang, Kun
Ai, Di
Liu, Guoqing
Yao, Wanru
Xie, Xingjuan
Gu, Hao
Zhen, Yingzi
Chen, Zhenping
Wu, Runhui
author_facet Sun, Jie
Li, Zekun
Li, Gang
Huang, Kun
Ai, Di
Liu, Guoqing
Yao, Wanru
Xie, Xingjuan
Gu, Hao
Zhen, Yingzi
Chen, Zhenping
Wu, Runhui
author_sort Sun, Jie
collection PubMed
description BACKGROUND: No studies evaluated the role of F8 mutations in outcomes for low‐dose immune tolerance induction (ITI) in people with severe hemophilia A (SHA) with high‐titer inhibitors. OBJECTIVES: To explore the association between F8 mutation types and low‐dose ITI outcomes in children with SHA with high‐titer inhibitors. METHODS: Children SHA with high‐titer inhibitors who received low‐dose ITI therapy at least for 1 year were included in this study. Based on the risk of inhibitor development, F8 mutations were classified into a high‐risk group and a non–high‐risk group. Rapid tolerance and the final ITI outcomes were assessed at the 12th and 24th month of treatment, respectively, and the predictor of outcomes was analyzed. RESULTS: Of 104 children included, 101 had F8 mutations identified. The children with non–high‐risk mutations presented a higher rate of rapid tolerance than those with high‐risk mutations (61.0% vs. 29.2%; p = 0.006). Among 72 children beyond 24 months of ITI, 55 children (76.4%) achieved success, 3 (4.2%) achieved partial success, and 14 (19.4%) failed. The children in the non–high‐risk group showed a higher success rate (86.8% vs. 43.8%; p = 0.001) and a shorter time to success (mean time, 9.3 months vs. 13.2 months; p = 0.04) compared to those in the high‐risk group. In multivariable logistic regression, F8 mutations were an independent predictor of ITI success (non–high‐risk group vs. high‐risk group, adjusted odds ratio [OR], 20.3; 95% confidence interval [CI], 3.5–117.8), as was the interval from inhibitor diagnosis to ITI start (adjusted OR, 0.95; 95% CI, 0.90–0.99). They remained the significant predictors when success time was taken into account in a Cox model. CONCLUSIONS: Types of F8 mutation were a key predictor of outcomes for low‐dose ITI in children with SHA with high‐titer inhibitors. It can help to stratify the prognosis and guide clinical decisions.
format Online
Article
Text
id pubmed-9606347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96063472022-10-28 Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes Sun, Jie Li, Zekun Li, Gang Huang, Kun Ai, Di Liu, Guoqing Yao, Wanru Xie, Xingjuan Gu, Hao Zhen, Yingzi Chen, Zhenping Wu, Runhui Res Pract Thromb Haemost Original Articles BACKGROUND: No studies evaluated the role of F8 mutations in outcomes for low‐dose immune tolerance induction (ITI) in people with severe hemophilia A (SHA) with high‐titer inhibitors. OBJECTIVES: To explore the association between F8 mutation types and low‐dose ITI outcomes in children with SHA with high‐titer inhibitors. METHODS: Children SHA with high‐titer inhibitors who received low‐dose ITI therapy at least for 1 year were included in this study. Based on the risk of inhibitor development, F8 mutations were classified into a high‐risk group and a non–high‐risk group. Rapid tolerance and the final ITI outcomes were assessed at the 12th and 24th month of treatment, respectively, and the predictor of outcomes was analyzed. RESULTS: Of 104 children included, 101 had F8 mutations identified. The children with non–high‐risk mutations presented a higher rate of rapid tolerance than those with high‐risk mutations (61.0% vs. 29.2%; p = 0.006). Among 72 children beyond 24 months of ITI, 55 children (76.4%) achieved success, 3 (4.2%) achieved partial success, and 14 (19.4%) failed. The children in the non–high‐risk group showed a higher success rate (86.8% vs. 43.8%; p = 0.001) and a shorter time to success (mean time, 9.3 months vs. 13.2 months; p = 0.04) compared to those in the high‐risk group. In multivariable logistic regression, F8 mutations were an independent predictor of ITI success (non–high‐risk group vs. high‐risk group, adjusted odds ratio [OR], 20.3; 95% confidence interval [CI], 3.5–117.8), as was the interval from inhibitor diagnosis to ITI start (adjusted OR, 0.95; 95% CI, 0.90–0.99). They remained the significant predictors when success time was taken into account in a Cox model. CONCLUSIONS: Types of F8 mutation were a key predictor of outcomes for low‐dose ITI in children with SHA with high‐titer inhibitors. It can help to stratify the prognosis and guide clinical decisions. John Wiley and Sons Inc. 2022-10-26 /pmc/articles/PMC9606347/ /pubmed/36313984 http://dx.doi.org/10.1002/rth2.12824 Text en © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Sun, Jie
Li, Zekun
Li, Gang
Huang, Kun
Ai, Di
Liu, Guoqing
Yao, Wanru
Xie, Xingjuan
Gu, Hao
Zhen, Yingzi
Chen, Zhenping
Wu, Runhui
Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
title Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
title_full Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
title_fullStr Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
title_full_unstemmed Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
title_short Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
title_sort low‐dose immune tolerance induction in children with severe hemophilia a with high‐titer inhibitors: type of factor 8 mutation and outcomes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606347/
https://www.ncbi.nlm.nih.gov/pubmed/36313984
http://dx.doi.org/10.1002/rth2.12824
work_keys_str_mv AT sunjie lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT lizekun lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT ligang lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT huangkun lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT aidi lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT liuguoqing lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT yaowanru lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT xiexingjuan lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT guhao lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT zhenyingzi lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT chenzhenping lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes
AT wurunhui lowdoseimmunetoleranceinductioninchildrenwithseverehemophiliaawithhightiterinhibitorstypeoffactor8mutationandoutcomes